Therefore, inhibitors of EGFR — inhibiting EGFR's kinase activity by competing with its cognate ligands — may potentially constitute a new class of effective drugs in clinical use or cancer therapy [12]–[14]. The gene discussed is EGFR; the disease is cancer.